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TAS-106 (ECyd, Fig. 1 ) is a new cytidine analogue showing significant cytotoxicity and antitumor activity in preclinical therapeutic models. [1] [2] [3] The results of several studies show that TAS-106 acts by interfering with RNA metabolism. 2, [4] [5] [6] [7] Further in vitro studies on RNA polymerase II, an enzyme expressed in the nuclear extracts from HeLa cells, revealed that the triphosphate of TAS-106, ECTP, inhibited in a concentration-dependent manner the activity of that enzyme. 4) The action of TAS-106 on RNA polymerase-specific transcription was demonstrated to be without specificity for RNA polymerase I, II or III in K562 human leukemia cells. 5) Moreover, in preliminary experiments, RNA polymerase was inhibited competitively by ECTP with a K i value of 21 nM (apparent K m value of CTP, 8.0 µM) in isolated nuclei of FM3A mouse mammary tumor cells. 6, 7) ECTP was found to accumulate as the major intracellular metabolite following the exposure of the cells to TAS-106 for 4 h and was then very slowly eliminated from the cells. 5, 6) Therefore, intracellular accumulation and retention of the active metabolite ECTP may contribute to the potent cytotoxicity of TAS-106. This profile, considered to reflect a unique mechanism of antitumor activity and cellular metabolism, makes TAS-106 different from other antitumor nucleosides and TAS-106 is a promising candidate as a therapeutic agent for cancer patients. The mechanisms of the antitumoral action of TAS-106 and its uracil analogue EUrd 1, 8) have been explored by Tabata et al. 4) using the EUrd-resistant variant, HT-1080/ EUrd, from HT-1080 human fibrosarcoma cells. They had reported that the HT-1080/EUrd cells showed cross-resistance to TAS-106 because uridine-cytidine kinase (UCK, EC 2.7.1.48) activity, the enzyme also responsible for the formation of active metabolites of TAS-106 (Fig. 2) , was down-regulated in HT-1080/EUrd cells when compared with the parental HT-1080 cells. Furthermore, Tsuji et al. had suggested that the alteration of the cellular membrane transport mechanism might partially contribute to the development of the resistance of HT-1080/EUrd cells. 9) We had expected a similar mechanism of resistance to E-mail: simamoto@taiho.co.jp occur in the case of TAS-106, but resistance induced by TAS-106 has not been reported yet. Therefore, to clarify the mechanism(s) of resistance and deepen knowledge on the mechanism of action of TAS-106, we made an attempt to develop TAS-106-and EUrd-resistant variants of DLD-1 human colon carcinoma and HT-1080 human fibrosarcoma cells. In the present study, we report the cellular and biochemical properties of these cancer cell lines with acquired resistance to TAS-106 and EUrd.
MATERIALS AND METHODS
Chemicals TAS-106, EUrd and 2′-deoxy-2′,2′-difluorocytidine (gemcitabine) were synthesized by Taiho Pharmaceutical Co., Ltd. (Tokyo). 5 Cell lines and cell culture The DLD-1 human colon carcinoma cell line, from the American Type Culture Collection (Manassas, VA), was purchased through Dainippon Pharmaceutical Co., Ltd. (Osaka). The HT-1080 human fibrosarcoma cell line and its EUrd-resistant variant HT-1080/EUrd were generous gifts from Professor Takuma Sasaki of the Cancer Research Institute, Kanazawa University (Kanazawa). A TAS-106-resistant variant of DLD-1, DLD-1/ECyd, was developed in our laboratory by continuous exposure of DLD-1 cells to TAS-106, starting with a concentration of 0.05 µM, which was stepwise increased to 1 µM. An EUrd-resistant variant of DLD-1, DLD-1/ EUrd, was developed by continuous exposure to EUrd, using the same conditions as indicated for DLD-1/ECyd cells. A TAS-106-resistant variant of HT-1080, HT-1080/ ECyd, was developed by continuous exposure to TAS-106, starting with a concentration of 0.05 µM, which was stepwise increased to 1 µM. DLD-1, DLD-1/ECyd, HT-1080, HT-1080/ECyd and HT-1080/EUrd cells were maintained in RPMI1640 medium supplemented with 10% heat-inactivated fetal calf serum (ICN Biomedicals, Inc., Aurora, OH) at 37°C and 5% CO 2 . DLD-1/EUrd cells were maintained in vitro in the medium containing 1 µM EUrd, though all further experiments were performed using cells grown in a drug-free medium for 7 days. Chemosensitivity testing The growth-inhibitory effects of test compounds on human cancer cells were determined by colorimetric assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent (Sigma). 10) Briefly, 180 µl aliquots of an exponentially growing cell suspension (0.5-2×10 3 cells/180 µl/well) were incubated in 96-well microplates for 24 h, then 20 µl of the drugs at various concentrations was added. After exposure to the drugs for 72 h, 25 µl of 2 mg/ml MTT reagent was added to each well, and the cell cultures were incubated at 37°C for 4 h. The medium was carefully removed and DMSO (150 µl) was added to each well to dissolve the formed formazan. After thorough mixing, the absorbance of each well was measured at 540 nm using a Model 3550 microplate reader (Bio-Rad Laboratories, Hercules, CA). Each experiment was performed using triplicate wells for each drug concentration and two or three independent experiments were carried out to confirm the reproducibility. The required drug concentration of IC 50 was determined by reducing the absorbance to 50% as compared to the control. Determination of RNA and DNA synthesis activity in whole cells Cells (1-2×10 4 cells/180 µl/well) were seeded in 96-well microplates and incubated for 24 h, and then 20 µl of TAS-106 was added. After 1 h treatment with TAS-106, 10 µl of [ 3 H]Guo, a precursor of RNA synthesis, or 10 µl of [ 3 H]dThd, a precursor of DNA synthesis, was added. Cells were incubated for another 3 h, washed three times with Dulbecco's PBS(−) (Nissui Pharmaceutical Co., Ltd., Tokyo) and then subjected to trypsinization to obtain a homogeneous cell suspension. The cell suspension in each well was aspirated from the microplate and deposited on a filter material attached to a rigid plate (UniFilter plate, Packard Instrument Co., Meriden, CT) using a cell harvester (FilterMate, Packard). Then the filter material was extensively washed with distilled water to destroy the cell membrane, and once with ethanol, followed by drying with blown air. The radioactivity of the filter plates was counted using a microplate scintillation counter (Top Counter, Packard) after the addition of 25 µl of liquid scintillator Microscint 40 (Packard).
Fig. 1. Structures of TAS-106 (A) and EUrd (B).
Each experiment was performed using 6 wells for each drug concentration and three independent experiments were carried out to confirm the reproducibility. Measurement of intracellular TAS-106 and its nucleotides by HPLC Cells (3×10 7 cells) were preincubated for 24 h at 37°C under 5% CO 2 atmosphere. [
3 H]TAS-106 or unlabeled TAS-106 was then added to the cells at a final drug concentration of 1 µM, and the cells were incubated for another 4, 6 or 8 h. Cells exposed to unlabeled TAS-106 were harvested in the same manner and suspended in Dulbecco's PBS(−) for cell counting. At the end of the incubation periods, the acid-soluble fraction containing cellular nucleotides was extracted with HClO 4 from the cells exposed to [ 3 H]TAS-106.
11) The acid-soluble fraction was neutralized with KOH and stored at −20°C until analysis by high-performance liquid chromatography (HPLC). The neutralized acid-soluble extracts were applied to a Partisil 10 SAX anion-exchange column (250×4.6 mm, Whatman, Inc., Clifton, NJ), and a linear gradient from 100% buffer A (0.005 M NH 4 H 2 PO 4 , pH 2.8) to 100% buffer B (0.5 M NH 4 H 2 PO 4 , pH 3.6) was run over 60 min at a rate of 2 ml/min. The elution profiles of TAS-106 and its nucleotides under these chromatographic conditions were determined by using external standards. The radioactivity associated with the respective nucleotides was measured with an on-line radioactive flow detector (FLO-ONE 500, Packard). The eluent was mixed automatically with scintillation fluid (Flo-Scint IV, Packard) at a ratio of 1:3. The amount of TAS-106 and its nucleotides in an extract was calculated based on the specific activity of [ 3 H]TAS-106. The experiments were repeated three times to confirm the reproducibility. Enzyme assay For determination of the intracellular activities of metabolic enzymes, test human cancer cells were collected during the logarithmic growth, and cell pellets were stored frozen at −135°C. Immediately before use, the pellets were thawed, supplemented with two volumes of 10 mM potassium phosphate buffer (pH 7.5) corresponding to their wet weights and then sonicated. The homogenates were centrifuged at 105 000g for 1 h at 4°C, and the supernatants (cytosol fractions) were collected. The cytosol fractions were divided into small portions and stored frozen at −80°C until use for enzyme assays. Enzyme assays were carried out according to the method of Ikenaka et al. 12) with a slight modification. All the experiments were done in duplicate. The reaction rates were linear with respect to time and enzyme concentration under the conditions employed. The experiments were repeated three times and the average of the three measurements is reported as the final value. The protein concentration in human cancer cell cytosols was measured by the Bradford method 13) using a Protein Assay Dye solution (Bio-Rad), with bovine serum albumin (BSA) serving as the reference protein.
Assay of Cyd and dCyd kinase
The reaction mixture, to a total volume of 125 µl, consisted of 50 mM Tris-HCl buffer (pH 8.0), 10 mM ATP (pH 7.5), 5 mM MgCl 2 , 10 mM NaF, 0.6 mM (0.25 µCi/tube) [ 3 H]Cyd or 0.2 mM (0.25 µCi/tube) [ 3 H]dCyd, and 50 µl of enzyme solution (cell cytosol). The reaction mixture was incubated at 37°C. The reaction was stopped by heating on a heating block at 105°C for 3 min. The sample was then centrifuged at 3000 rpm for 10 min at 4°C. The supernatant, 10 µl, was spotted onto a polyethyleneimine (PEI)-cellulose F thin layer chromatography (TLC) plate (2.5×10 cm, Merck KGaA, Darmstadt, Germany) and developed with water. The phosphorylated Cyd or dCyd, remaining at the point of origin, was harvested into a vial and combined with 0.5 ml of 1 M HCl. The mixture was then combined with 10 ml of liquid scintillator ACS-II (Amersham) for radioactivity measurement using a Wallac 1414 WinSpectral liquid scintillation counter (Wallac Berthold Japan Co., Ltd., Tokyo). Assay of CMP kinase The reaction mixture, to a total volume of 125 µl, consisted of 50 mM Tris-HCl buffer (pH 8.0), 10 mM ATP (pH 7.5), 5 mM MgCl 2 , 10 mM dithiothreitol, 1 mM (0.25 µCi/tube) [ 3 H]CMP, 1 mg/ml BSA and 50 µl of enzyme solution. The reaction mixture was incubated at 37°C. The reaction was stopped by heating on a heating block at 105°C for 3 min. The sample was then centrifuged at 3000 rpm for 10 min at 4°C. The supernatant, 10 µl, was spotted onto a PEI-cellulose F TLC plate (3×10 cm, Merck) and developed with a mixture of 1 M acetic acid and 1 M lithium chloride (1:1, v/v). Authentic samples of CMP, CDP and CTP were applied to the plate before the test sample and were visualized under a UV lamp. The spots corresponding to CDP and CTP were harvested into vials and taken up in 0.5 ml of 1 M HCl, then the radioactivity was measured as described above. Tables I and II show the results of chemosensitivity testing and metabolic enzyme assays, respectively, in 6 cancer cell lines. When cells were exposed to TAS-106 for 72 h, the IC 50 values were 0.058 µM for DLD-1, 6.088 µM for DLD-1/ECyd and 2.387 µM for DLD-1/EUrd cells. Therefore, the degree of resistance to TAS-106 for these two resistant cells was calculated to be 105 and 41, respectively. Similarly, the IC 50 values at 72 h exposure were 0.027 µM for HT-1080, 8.299 µM for HT-1080/ECyd and 29.76 µM for HT-1080/EUrd cells. Therefore, the degree of resistance to TAS-106 for these two resistant cells was calculated to be 307 and 1102, respectively. Cross-resistance was observed to EUrd in TAS-106-resistant cells, and to TAS-106 in EUrd-resistant cells developed from both DLD-1 and HT-1080 cells. Since the UCK activity measured using Cyd as a substrate was down-regulated from 1/3 to 1/24 in these TAS-106-and EUrd-resistant cells as compared with the respective parental cells, cross-resistance was also observed for FUR, as Tabata et al. reported. 4) Unexpectedly, a slight increase in sensitivity to gemcitabine, a dCyd analogue phosphorylated to an active form by dCyd kinase (Fig. 2) , [14] [15] [16] Enzyme activities are mean±SD of three individual experiments. a) The decrease (fold) in enzyme activity of resistant variants as compared to the respective parental cell lines. (Fig. 4B) and DLD-1/EUrd (Fig. 4C) 1-3) Thus, TAS-106 is a promising candidate as a therapeutic agent for cancer treatment. To apply TAS-106 clinically, it seems to be important to know the cellular and biochemical mechanisms of cancer cells resistance to TAS-106. Tabata et al. 4) have established an HT-1080/ EUrd cell variant resistant to EUrd, a compound presumably activated by UCK. We expected a similar mechanism of resistance to occur in the case of TAS-106, though no such cell variant has as yet been observed. In the present study, we have therefore established several cell variants resistant to TAS-106 or EUrd to study the mechanism(s) of TAS-106 resistance. The growth rates of these resistant variants, DLD-1/ECyd, DLD-1/EUrd, HT-1080/ECyd and HT-1080/EUrd, were not significantly changed as compared to those of the respective parental cell lines, DLD-1 and HT-1080 (data not shown).
RESULTS

Chemosensitivity and metabolic enzyme activities of human cancer cells
As shown in Fig. 1 , TAS-106 is a Cyd analogue with an acetylene group at the 3′-position in the ribose moiety, and EUrd is its uracil analogue. 1, 8) It has been suggested that TAS-106 and EUrd might have a similar mechanism of action, based on mean graph analysis, which revealed that the two compounds show similar inhibitory spectra against various human cancer cell lines in vitro. 1) This idea was proved to be true since cross-resistance was actually observed to EUrd in TAS-106-resistant cells, and to TAS-106 in EUrd-resistant cells. Both ribo-nucleoside analogues, TAS-106 and EUrd, must be phosphorylated by UCK to exert cytotoxic effects, as illustrated in Fig. 2 . In the TAS-106-and EUrd-resistant cells, the UCK activity was down-regulated as compared with the respective parental cells, while the UMP-CMP kinase activity was not much changed. TAS-106 and EUrd are largely resistant to inactivation by Cyd deaminase and uridine phosphorylase, respectively (data not shown). Therefore, the decrease in UCK activity in these resistant cells was expected to be a main cause of resistance to TAS-106 and EUrd. Cross-resistance was also observed for FUR, and not for 5-FU. These results suggest that FUR and 5-FU are probably phosphorylated to their monophosphate, 5-fluorouridine 5′-monophosphate (FUMP), through different pathways in human cancer cells. As shown in Fig. 2 , FUR may be phosphorylated in human cancer cells to FUMP by UCK, while 5-FU may be phosphorylated to FUMP by orotate phosphoribosyltransferase. 17) TAS-106 concentration-dependently inhibited RNA synthesis, while its effect on DNA synthesis was negligible. The IC 50 values for inhibitory effect of TAS-106 on RNA synthesis following 4 h drug exposure were 13 to 219 times higher than the IC 50 values for chemosensitivity testing following 72 h exposure to TAS-106, but the degree of resistance calculated from the inhibitory effect on RNA synthesis in TAS-106-and EUrd-resistant cells tended to be close to the degree of chemoresistance to TAS-106.
When we measured the intracellular accumulation of TAS-106 metabolites, the amount of TAS-106 transported into the parental DLD-1 and HT-1080 cells increased linearly with time up to 6 or 8 h and ECTP was detected as the major metabolite in both cells. The other TAS-106 metabolites included ECDP, ECMP and unmetabolized TAS-106, in descending order, and each of the metabolites remained almost unchanged with time as a percentage of the total metabolites derived from TAS-106. These results suggest that TAS-106 is rapidly phosphorylated to ECMP, ECDP and ECTP after being taken up by DLD-1 and HT-1080 cells. On the contrary, the amount of TAS-106 taken up by TAS-106-and EUrd-resistant cells was markedly reduced. Additionally, the levels of TAS-106 and its nucleotides reached plateaus within 4 h exposure to TAS-106 in these resistant variants, indicating the presence of intracellular regulatory mechanism(s) maintaining the amount of TAS-106 transported into these cells at constant levels. Thus, the alteration of nucleoside transport mechanisms, both decrease in uptake and increase in efflux, may be one of the important factors for acquisition of resistance by cancer cells to TAS-106 and EUrd, as suggested by Tsuji et al. 9) Moreover, the unmetabolized TAS-106 as a percentage of the total intracellular metabolite level was much higher in these TAS-106-and EUrd-resistant cells than in their parental cells. The apparent increase in the accumulation of unmetabolized TAS-106 is caused by the down-regulation of UCK activity, which in turn prevents the further metabolic step to ECTP, an active metabolite that is unable to leave the cell due to the presence of the phosphate function. The activity of UCK is actually several-fold decreased in the resistant variants, though at this stage it is difficult to conclude whether this is due to decreased expression at the protein level or altered affinity of the enzyme for TAS-106. Consequently, the ratio of the intracellular level of ECTP after 4 h treatment with 1 µM TAS-106 in the resistant cells to that of the respective parental cells tended to approximate to the degree of resistance calculated from the inhibitory effect of TAS-106 on RNA synthesis after 4 h exposure.
In conclusion, the sensitivity of the cells to TAS-106 was correlated with the inhibition of cellular RNA synthesis by TAS-106, and further the inhibition of cellular RNA synthesis by TAS-106 was correlated with the intracellular accumulation of ECTP. In addition, we consider that both alterations of cellular membrane transport (decrease in uptake and increase in efflux) and intracellular phosphorylation (down-regulation of UCK activity) are involved in the development of the resistance of cancer cells to TAS-106 or EUrd. 
